Difference between Regorafenib, 5FU, and TAS-102
Howard S. Hochster, MD of Yale Cancer Center discusses the difference between Regorafenib, 5FU, and TAS-102 at the 2017 Gastrointestinal Cancers Symposium (ASCO GI) in San Francisco, CA.
Author: obr
Added: 01/24/2017 (Source: Oncology Tube)
Source: Oncology Tube - January 24, 2017 Category: Cancer & Oncology Source Type: podcasts
How Will Checkpoint Inhibitors Be Incorporated Into Unresectable HCC Treatment
Ghassan Abou-Alfa, MD, MBA of Memorial Sloan Kettering gives his view on checkpoint inhibitors and their incorporation into treatment for unresectable HCC at the 2017 Gastrointestinal Cancers Symposiu...
Author: obr
Added: 01/24/2017 (Source: Oncology Tube)
Source: Oncology Tube - January 24, 2017 Category: Cancer & Oncology Source Type: podcasts
ASCO GI 2017: Subgroups for HCC Targeted Therapies
Ghassan Abou-Alfa, MD, MBA of Memorial Sloan Kettering Cancer Center discusses his view on reliably identifying subgroups of patients for targeted therapies in HCC at the 2017 Gastrointestinal Cancers...
Author: obr
Added: 01/24/2017 (Source: Oncology Tube)
Source: Oncology Tube - January 24, 2017 Category: Cancer & Oncology Source Type: podcasts
Will Physicians Incorporate Regorafenib Into Clinical Practice
Ghassan Abou-Alfa, MD, MBA of Memorial Sloan Kettering Cancer Center discusses his thoughts on whether or not physicians will start incorporating regorafenib into clinical practice at the 2017 Gastroi...
Author: obr
Added: 01/24/2017 (Source: Oncology Tube)
Source: Oncology Tube - January 24, 2017 Category: Cancer & Oncology Source Type: podcasts
ASCO GI 2017: RESORCE Trial Outcomes
Ghassan Abou-Alfa, MD, MBA of Memorial Sloan Kettering Cancer Center gives his take on the outcomes of the RESORCE trial, which was presented at the 2017 Gastrointestinal Cancers Symposium (ASCO GI) i...
Author: obr
Added: 01/24/2017 (Source: Oncology Tube)
Source: Oncology Tube - January 24, 2017 Category: Cancer & Oncology Source Type: podcasts
Integration of New Agents for Advanced HCC Treatment
Ghassan Abou-Alfa, MD, MBA of Memorial Sloan Kettering Cancer Center gives his take on integration of new agents for advanced HCC treatment at the 2017 Gastrointestinal Cancers Symposium (ASCO GI) in ...
Author: obr
Added: 01/24/2017 (Source: Oncology Tube)
Source: Oncology Tube - January 24, 2017 Category: Cancer & Oncology Source Type: podcasts
Use of Checkpoint Inhibitors in Unresectable HCC
Nevena Damjanov, MD of University of Pennsylvania talks about how checkpoint inhibitors will be incorporated into unresectable HCC treatment at the 2017 Gastrointestinal Cancers Symposium (ASCO GI) in...
Author: obr
Added: 01/24/2017 (Source: Oncology Tube)
Source: Oncology Tube - January 24, 2017 Category: Cancer & Oncology Source Type: podcasts
Identifying Subgroups of Patients for Targeted Therapies in HCC
Nevena Damjanov, MD of University of Pennsylvania discusses how healthcare professionals can reliably identify subgroups of patients for targeted therapies in HCC at the 2017 Gastrointestinal Cancers ...
Author: obr
Added: 01/24/2017 (Source: Oncology Tube)
Source: Oncology Tube - January 24, 2017 Category: Cancer & Oncology Source Type: podcasts
Regorafenib In Clinical Practice
Nevena Damjanov, MD of University of Pennsylvania discusses how regorafenib will be incorporated into clinical practice at 2017 Gastrointestinal Cancers Symposium (ASCO GI) in San Francisco, CA.
Author: obr
Added: 01/24/2017 (Source: Oncology Tube)
Source: Oncology Tube - January 24, 2017 Category: Cancer & Oncology Source Type: podcasts
Outcomes of RESORCE Trial at ASCO GI 2017
Nevena Damjanov, MD of University of Pennsylvania gives an overview of the outcomes of the RESORCE Trial that were presented at the 2017 Gastrointestinal Cancers Symposium (ASCO GI) in San Francisco, ...
Author: obr
Added: 01/24/2017 (Source: Oncology Tube)
Source: Oncology Tube - January 24, 2017 Category: Cancer & Oncology Source Type: podcasts
New Agents for Advanced HCC Treatment
Nevena Damjanov, MD of University of Pennsylvania discusses how new agents being studied for advanced HCC will be integrated into treatment at the 2017 Gastrointestinal Cancers Symposium (ASCO GI) in ...
Author: obr
Added: 01/24/2017 (Source: Oncology Tube)
Source: Oncology Tube - January 24, 2017 Category: Cancer & Oncology Source Type: podcasts
Proprietary Neoantigen Identification Technology Platform
Johanna Bendell, MD of Sarah Cannon Research Institute discusses the Proprietary Neoantigen Identification Technology Platform at the 2017 Gastrointestinal Cancers Symposium (ASCO GI) in San Francisco...
Author: obr
Added: 01/23/2017 (Source: Oncology Tube)
Source: Oncology Tube - January 23, 2017 Category: Cancer & Oncology Source Type: podcasts
ASCO GI 2017: Data from RESORCE Trial
Johanna Bendell, MD of Sarah Cannon Research Institute discusses the RESORCE Trial and how its data can change treatment for the patient population today at the 2017 Gastrointestinal Cancers Symposium...
Author: obr
Added: 01/23/2017 (Source: Oncology Tube)
Source: Oncology Tube - January 23, 2017 Category: Cancer & Oncology Source Type: podcasts
Challenges in Treating Pancreatic Cancer
Johanna Bendell, MD of Sarah Cannon Research Institute discusses the challenges she's faced in treating pancreatic cancer at the 2017 Gastrointestinal Cancers Symposium (ASCO GI) in San Francisco, CA.
Author: obr
Added: 01/23/2017 (Source: Oncology Tube)
Source: Oncology Tube - January 23, 2017 Category: Cancer & Oncology Source Type: podcasts
Trial and Drug Development in Pancreatic Cancer
Johanna Bendell, MD of Sarah Cannon Research Institute discusses the upcoming trial and drug development in pancreatic and gastrointestinal cancers at the 2017 Gastrointestinal Cancers Symposium (ASCO...
Author: obr
Added: 01/23/2017 (Source: Oncology Tube)
Source: Oncology Tube - January 23, 2017 Category: Cancer & Oncology Source Type: podcasts
